Sign up to save your podcasts
Or
Share Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored
In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.
View all episodes
By Rahul Banerjee, MD
4.8
2727 ratings
In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.
More shows like The HemOnc Pulse
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
322 Listeners
JAMA Clinical Reviews
498 Listeners
Hematologic Oncology Update
76 Listeners
Research To Practice | Oncology Videos
121 Listeners
The Hematologist
28 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
OncoPharm
187 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Blood Podcast
52 Listeners
Healthcare Unfiltered
138 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
193 Listeners
WolverHeme Happy Hour
31 Listeners